Artiva Biotherapeutics, Inc.
ARTVDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ARTV Earnings Report
EPS Est: $-0.64 | FQ end 2026-06
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Allogeneic NK Cells | Phase 2 | Refractory Rheumatoid Arthritis (RA) | - | - |
AB-101 | Phase 2 | Non Hodgkin Lymphoma | - | - |
Refractory Rheumatoid Arthritis (RA)
1 drug in this indication
Non Hodgkin Lymphoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Artiva Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Artiva Biotherapeutics, Inc.'s (ARTV) pipeline across Phase 2. Its lead program is Allogeneic NK Cells (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Artiva Biotherapeutics, Inc.'s next FDA catalyst?→
Artiva Biotherapeutics, Inc.'s (ARTV) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARTV biotech catalysts?→
Add ARTV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Artiva Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.